Wait-and-see approach in a paediatric patient with Neuroblastoma with Metastatic Disease

Authors

DOI:

https://doi.org/10.25753/BirthGrowthMJ.v34.i1.33107

Keywords:

adrenal gland, hepatomegaly, neuroblastoma, wait-and-see approach

Abstract

Neuroblastoma is the most common extracranial solid tumour in the paediatric population, accounting for approximately 8-10% of all childhood cancers. It arises from the abnormal proliferation of embryonic neural crest cells which normally give rise to the sympathetic nervous system (SNS) and the adrenal gland medulla. Its prognosis is uniquely heterogeneous, with some children experiencing spontaneous regression, while others develop widespread metastatic disease with poor outcomes despite aggressive multimodal therapy. Treatment choice dependents on risk stratification based on the patient’s age at diagnosis and tumour characteristics, such as stage and biological features.

We describe the case of an infant who presents with hepatic metastasis secondary to a solid tumour in the left adrenal gland, classified as stage MS according to the INRGSS classification. A wait-and-see approach was adopted, with clinical, analytic and radiologic surveillance, verifying spontaneous regression of the tumour afterwards.

Downloads

References

Sharma R, Mer J, Lion A, Vik TA. Clinical Presentation, Evaluation, and Management of Neuroblastoma. Peds in Review. 2018;39(4):194-203. https://doi:10.1542/pir.2017-0087.

Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17(4):369-86. https://doi:10.1080/14737140.2017.1285230.

Ishola TA, Chung DH. Neuroblastoma. Surg Oncol. 2007; 16(3):149-156. https://doi:10.1016/j.suronc.2007.09.005.

Ahmed AA, Zhang L, Reddivalla N, Hetherington M. Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors. Pediatr Hematol Oncol. 2017;34(3):165-85. https://doi:10.1080/08880018.2017.1330375.

Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. J Clin Oncol. 2009;27(2):298-303. https://doi:10.1200/JCO.2008.16.6876.

Pinto NR, Applebaum MA, Volchenbaum SL, Matthay KK, London WB, Ambros PF, et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015;33(27):3008-18. https://doi:10.1200/JCO.2014.59.4648.

Bansal D, Totadri S, Chinnaswamy G, Agarwala S, Vora T, Arora B, et al. Management of Neuroblastoma: ICMR Consensus Document. Indian J Pediatr. 2017;84(6):446-455. https://doi:10.1007/s12098-017-2298-0.

Brodeur GM. Spontaneous regression of neuroblastoma. Cell Tissue Res. 2018;372(2):277–86. https://doi:10.1007/s00441-017-2761-2.

Bhatnagar SN, Sarin YK. Neuroblastoma: A Review of Management and Outcome. Indian J Pediatr. 2012; 79(6):787-92. https://doi:10.1007/s12098-012-0748-2.

Louis CU, Shohet JM. Neuroblastoma: Molecular Pathogenesis and Therapy. Annu Rev Med. 2015;66:49-63. https://doi:10.1146/annurev-med-011514-023121.

Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O'Neill S, et al. A comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumours. J Clin Oncol. 2001 Jun 15;19(12):3080-90.

“Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97”, J Clin Oncol. 2008;26(9):1504-10.

De Bernardi B, Mosseri V, Rubie H, et al. Treatment of localised resectable neuroblastoma: results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer 2008;99(7):1027–33.

Downloads

Published

2025-04-07

How to Cite

1.
Moreira B, Foles A, Silva D, Gonçalves P. Wait-and-see approach in a paediatric patient with Neuroblastoma with Metastatic Disease . REVNEC [Internet]. 2025Apr.7 [cited 2025Apr.20];34(1):34-8. Available from: https://revistas.rcaap.pt/nascercrescer/article/view/33107

Issue

Section

Case Reports

Most read articles by the same author(s)